| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
HeparinNeoplasia (Oncology BASKET)| 1 | 1999 | Actions of heparin that may affect the malignant process. | 
| + | - | nl | Cancer 85(2):257-72 (1999) |
| 2 | 2005 | Low-molecular-weight heparin and survival in patients with malignant disease. |
| + | - | nl | Cancer Control 12 Suppl 1(-):22-30 (2005) |
| 3 | 2008 | [Pharmacology of heparins and direct anticoagulants]. |
| + | - | nl | Hamostaseologie 28(5):400-20 (2008) |
| 4 | 2007 | The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. | 
| + | - | nl | J Thromb Haemost 5(4):729-37 (2007) |
| 5 | 2000 | Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells. |
| + | - | nl | Am J Physiol Lung Cell Mol Physiol 279(5):L779-89 (2000) |
| 6 | 2001 | Mechanism of action and pharmacology of unfractionated heparin. |
| + | - | nl | Arterioscler Thromb Vasc Biol 21(7):1094-6 (2001) |
| 7 | 1979 | Heparin: new concepts relevant to clinical use. |
| + | - | nl | Blood 53(4):525-44 (1979) |
| 8 | 2001 | Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. |
| + | - | nl | Chest 119(1 Suppl):64S-94S (2001) |
| 9 | 1999 | Clinical uses of low-molecular-weight heparins. |
| + | - | nl | Chest 115(5):1418-23 (1999) |
| 10 | 1998 | Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. |
| + | - | nl | Chest 114(5 Suppl):489S-510S (1998) |
| 11 | 1992 | Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. |
| + | - | nl | Chest 102(4 Suppl):337S-351S (1992) |
| 12 | 2001 | Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. |
| + | - | nl | Circulation 103(24):2994-3018 (2001) |
| 13 | 2008 | Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. |
| + | - | nl | Diabetes Care 31 Suppl 2(-):S202-7 (2008) |
| 14 | 2002 | Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. |
| + | - | nl | Haematologica 87(7):757-70 (2002) |
| 15 | 2005 | The heparins: all a nephrologist should know. |
| + | - | nl | Nephrol Dial Transplant 20(10):2036-42 (2005) |
| 16 | 1999 | Therapeutic uses of heparinoids in renal disease patients. |
| + | - | nl | Nephrol Dial Transplant 14(3):540-3 (1999) |
| 17 | 2009 | Low-molecular-weight heparin in patients with renal insufficiency. |
| + | - | nl | Swiss Med Wkly 139(31-32):438-52 (2009) |
| 18 | 1982 | The risks and benefits of heparin therapy. |
| + | - | nl | West J Med 136(3):241-2 (1982) |
| 19 | 1995 | Heparin lowers blood pressure: biological and clinical perspectives. |
| + | - | nl | Kidney Int 47(4):1017-22 (1995) |
